NZ610638A - Pharmaceutical compositions comprising radezolid - Google Patents

Pharmaceutical compositions comprising radezolid

Info

Publication number
NZ610638A
NZ610638A NZ610638A NZ61063811A NZ610638A NZ 610638 A NZ610638 A NZ 610638A NZ 610638 A NZ610638 A NZ 610638A NZ 61063811 A NZ61063811 A NZ 61063811A NZ 610638 A NZ610638 A NZ 610638A
Authority
NZ
New Zealand
Prior art keywords
radezolid
pharmaceutical compositions
disintegrant
prodrug
lubricant
Prior art date
Application number
NZ610638A
Other languages
English (en)
Inventor
Danping Li
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of NZ610638A publication Critical patent/NZ610638A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ610638A 2010-11-24 2011-11-21 Pharmaceutical compositions comprising radezolid NZ610638A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41680710P 2010-11-24 2010-11-24
PCT/US2011/061643 WO2012071324A2 (en) 2010-11-24 2011-11-21 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NZ610638A true NZ610638A (en) 2015-05-29

Family

ID=46146374

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ610638A NZ610638A (en) 2010-11-24 2011-11-21 Pharmaceutical compositions comprising radezolid

Country Status (21)

Country Link
US (2) US20140088164A1 (https=)
EP (1) EP2642996B1 (https=)
JP (2) JP6370550B2 (https=)
KR (1) KR101944124B1 (https=)
CN (1) CN103391778B (https=)
AU (1) AU2011332031B2 (https=)
BR (1) BR112013012833A8 (https=)
CA (1) CA2818249C (https=)
EA (1) EA027791B1 (https=)
ES (1) ES2836809T3 (https=)
HU (1) HUE052801T2 (https=)
IL (1) IL226378A0 (https=)
MX (1) MX350565B (https=)
MY (2) MY182136A (https=)
NZ (1) NZ610638A (https=)
PH (1) PH12013501069A1 (https=)
PT (1) PT2642996T (https=)
SG (2) SG10201509530YA (https=)
UA (1) UA113722C2 (https=)
WO (1) WO2012071324A2 (https=)
ZA (1) ZA201303732B (https=)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
ES2312422T3 (es) 2000-03-22 2009-03-01 PHARMACIA & UPJOHN COMPANY LLC Formulacion de comprimido de oxazolidinona.
PE20011088A1 (es) 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
BR0111280A (pt) 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
BR0112393A (pt) * 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
CA2431319A1 (en) 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
JP5043428B2 (ja) 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ,インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
AR046782A1 (es) 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
CN101272769B (zh) 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
US20070026072A1 (en) * 2005-07-28 2007-02-01 Stephen Olsen Benzoquinones of enhanced bioavailability
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
JP5773560B2 (ja) 2006-02-09 2015-09-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Cetp阻害剤のポリマー製剤
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
SG10201406571YA (en) * 2009-10-13 2014-11-27 Melinta Therapeutics Inc Pharmaceutical compositions
JP5792807B2 (ja) * 2010-06-14 2015-10-14 ダウ グローバル テクノロジーズ エルエルシー アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート
EP2635307B1 (en) 2010-11-01 2020-07-29 Melinta Subsidiary Corp. Pharmaceutical compositions

Also Published As

Publication number Publication date
US20160374995A1 (en) 2016-12-29
KR101944124B1 (ko) 2019-01-30
CN103391778B (zh) 2016-04-20
WO2012071324A2 (en) 2012-05-31
SG10201509530YA (en) 2015-12-30
AU2011332031A1 (en) 2013-06-06
HUE052801T2 (hu) 2021-05-28
IL226378A0 (en) 2013-07-31
KR20140033314A (ko) 2014-03-18
JP6370550B2 (ja) 2018-08-08
EA201390764A1 (ru) 2013-09-30
PH12013501069A1 (en) 2013-07-08
JP2017081950A (ja) 2017-05-18
EA027791B1 (ru) 2017-09-29
BR112013012833A2 (pt) 2016-08-23
CA2818249A1 (en) 2012-05-31
CA2818249C (en) 2021-04-13
JP2013543893A (ja) 2013-12-09
EP2642996A4 (en) 2014-05-21
SG190354A1 (en) 2013-06-28
EP2642996A2 (en) 2013-10-02
MY182136A (en) 2021-01-18
ZA201303732B (en) 2018-12-19
EP2642996B1 (en) 2020-09-23
MX2013005813A (es) 2013-09-13
AU2011332031B2 (en) 2017-01-12
CN103391778A (zh) 2013-11-13
US20140088164A1 (en) 2014-03-27
PT2642996T (pt) 2020-12-30
MY171941A (en) 2019-11-08
WO2012071324A3 (en) 2012-08-16
US10300046B2 (en) 2019-05-28
UA113722C2 (uk) 2017-03-10
ES2836809T3 (es) 2021-06-28
MX350565B (es) 2017-09-11
BR112013012833A8 (pt) 2018-01-02

Similar Documents

Publication Publication Date Title
EP4374878A3 (en) Pharmaceutical composition
PH12012501622A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2012009723A8 (en) C-met modulator pharmaceutical compositions
MX2013001677A (es) Formulaciones estables de linaclotida.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
SI2616076T1 (sl) Farmacevtski sestavki
PH12015501096A1 (en) Composition for immediate and extended release
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
MY156518A (en) Borinic compositions
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
ZA201108292B (en) New compounds,pharmaceutical composition and methods relating thereto
IL222092B (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
ZA201105572B (en) Pharmaceutical composition for oral administration
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
EP2582396A4 (en) REMEDY FORMULATIONS WITH LONG-TERM EFFECT
IL222707B (en) Steroid compounds of 16-chloro- and 16, 16-dichloro-(4-alpha, 4-beta)-17-beta-(2-oxo-2h-pyran-5-yl) and pharmaceutical preparations containing them
IL212171A (en) 1-Phenylpyrol compounds, pharmaceuticals containing them and their use
IL206739A (en) An injectable drug containing silitol as an active substance
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2016 BY CULLENS

Effective date: 20150918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2017 BY COMPUTER PACKAGES INC

Effective date: 20161101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2018 BY COMPUTER PACKAGES INC

Effective date: 20171031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2019 BY COMPUTER PACKAGES INC

Effective date: 20181031

LAPS Patent lapsed